InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ‘ Global Rituximab Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2027’
Request for ToC/Proposal: http://www.insightaceanalytic.com/report-details/104-rituximab-biosimilar-market-research-report/#request-for-tocproposal
Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the normal and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma as well as autoimmune disorder such as Rheumatoid arthritis. Rituximab is marketed under the trade name of MabThera in Europe and rest of World, except Japan by Roche. In the United States it marketed as Rituxan by Genentech in partnership with Biogen Idec. In Japan it is marketed by Chugai and Zenyaku Kogyo Co. Ltd. It is approved in the U.S. in 1997 and by European Medical Agency in June 1998. Rituximab is one of the top selling pharmaceutical product of Roche Holding AG. Therefor many biosimilar pharmaceutical companies are focusing on product development of rituximab biosimilar to compel the biosimilar product market share.
The rituximab biosimilar market is expected to grow at higher pace during forecast period,since the rituximab is one of the best seller drug product that accounts for around 2.1 million prescriptions worldwide since the market launch. In addition, rituximab has lost its patent in the United States and Europe in 2016 and 2013 respectively.
The Rituximab biosimilar market is fragmented with presence of many players that operates in local as well as international market.
Global Rituximab biosimilar Market reports cover prominent players like Amgen, AryoGen Pharmed, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Teva Pharmaceutical, Intas Biopharmaceuticals, JHL Biotech, mAbxience SA., Mylan, Pfizer, Sandoz, Zenotech Laboratories and many more.
Curious about this latest version of report?
Obtain Report Details @ http://www.insightaceanalytic.com/report-details/104-rituximab-biosimilar-market-research-report/#request-for-tocproposal
Market Segments
- Global Rituximab biosimilar Market Outlook (Revenue, US$ Mn, 2017 – 2027) By Application
- Non-Hodgkin’s lymphoma,
- Chronic Lymhocytic Leukemia,
- Rheumatoid arthritis and others
- Global Rituximab Biosimilar Market Outlook (Revenue, US$ Mn, 2017 – 2027) By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Other Direct Distribution Channels
Why should buy this report:
- To receive a comprehensive analysis of the prospects for global Rituximab biosimilar market
- To receive industry overview and future trends Rituximab biosimilar market
- To analyze the Rituximab biosimilar market drivers and challenges
- To get information on Rituximab biosimilar market size and forecast
- To get details on Rituximab biosimilar clinical trial/pipeline analysis
- Originator drug historic revenue
- Originator drug key news/industry activities
- Major Mergers & Acquisition in Rituximab biosimilar industry
For More Information @ http://www.insightaceanalytic.com/report-details/104-rituximab-biosimilar-market-research-report/#request-for-tocproposal
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
Email us: info@insightaceanalytic.com
Call: +1 718 593 4405
Website: www.insightaceanalytic.com
Your information will never be shared with any third party.